AU4418400A - Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin - Google Patents

Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin

Info

Publication number
AU4418400A
AU4418400A AU44184/00A AU4418400A AU4418400A AU 4418400 A AU4418400 A AU 4418400A AU 44184/00 A AU44184/00 A AU 44184/00A AU 4418400 A AU4418400 A AU 4418400A AU 4418400 A AU4418400 A AU 4418400A
Authority
AU
Australia
Prior art keywords
alfa5
integrin
binds
diagnosis
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44184/00A
Inventor
Roy Bicknell
Hua-Tang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Horizons Ltd
Original Assignee
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Cancer Research Technology Ltd filed Critical Imperial Cancer Research Technology Ltd
Publication of AU4418400A publication Critical patent/AU4418400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU44184/00A 1999-04-24 2000-04-13 Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin Abandoned AU4418400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9909392.4A GB9909392D0 (en) 1999-04-24 1999-04-24 Treatment, imaging and diagnosis of disease
GB9909392 1999-04-24
PCT/GB2000/001446 WO2000064480A1 (en) 1999-04-24 2000-04-13 Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin

Publications (1)

Publication Number Publication Date
AU4418400A true AU4418400A (en) 2000-11-10

Family

ID=10852148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44184/00A Abandoned AU4418400A (en) 1999-04-24 2000-04-13 Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin

Country Status (3)

Country Link
AU (1) AU4418400A (en)
GB (1) GB9909392D0 (en)
WO (1) WO2000064480A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043340A2 (en) * 2002-07-16 2004-05-27 University Of Medicine And Dentistry Of New Jersey Alpha 5 beta 1 and its ability to regulate the cell survival pathway
WO2004069281A1 (en) * 2003-01-30 2004-08-19 The General Hospital Corporation Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders
ES2539126T3 (en) * 2004-12-09 2015-06-26 Janssen Biotech, Inc. Anti integrin immunoconjugates, methods for their production and use
MX2008011905A (en) 2006-03-21 2008-09-30 Genentech Inc Combinatorial therapies.
US20080038190A1 (en) * 2006-08-11 2008-02-14 Simpson Thomas J Composition apparatus and method for use in imaging
SI2200700T1 (en) 2007-09-26 2016-04-29 Genentech, Inc. Novel antibodies
RU2011142974A (en) 2009-03-25 2013-04-27 Дженентек, Инк. NEW ANTIBODIES AGAINST α5β1 AND THEIR APPLICATION
EP3365353B1 (en) 2015-10-23 2023-11-22 Universiteit Twente Integrin binding peptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
JP2002514605A (en) * 1998-05-08 2002-05-21 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Methods for detecting and inhibiting angiogenesis

Also Published As

Publication number Publication date
WO2000064480A1 (en) 2000-11-02
GB9909392D0 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
AU2001262943A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2002362608A1 (en) Cardiac catheter imaging system
AU5902500A (en) Destruction pulse ultrasound contrast agent imaging
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
AU2001235018A1 (en) Medical diagnostic ultrasound system using contrast pulse sequence imaging
AU2001227815A1 (en) Chemically specific imaging of tissue
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
GB9909966D0 (en) Analysis of fundus images
AU2003223172A1 (en) Use of the axl receptor for diagnosis and treatment of renal disease
AU2003286726A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU4418400A (en) Treatment, imaging and diagnosis of disease using an agent which binds alfa5-integrin
AU2003210266A1 (en) Treatment, diagnosis and imaging of disease
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU4204700A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU4654500A (en) Prevention, diagnosis and treatment of lyme disease
AU1820499A (en) Compounds and methods for the diagnosis and treatment of (b. microti) infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase